Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting
- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and…
Deltek Celebrates the 18th Annual Most Valuable Project Award Winners at Deltek ProjectCon 2025
Global leaders across architecture, engineering, construction, consulting, and government contracting recognized for…
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.…
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
November 03, 2025 16:45 ET | Source: Fulcrum Therapeutics, Inc. ― Pociredir…
Xinhua Silk Road: Annual Conference of Financial Street Forum 2025 concludes with fruitful results
BEIJING, Nov. 3, 2025 /PRNewswire/ -- The Annual Conference of Financial Street…
Xinhua Silk Road: Annual Conference of Financial Street Forum 2025 kicks off Monday, highlighting high-quality global financial development
BEIJING, Oct. 30, 2025 /PRNewswire/ -- The Annual Conference of Financial Street…
PARTNERSHIP ANNUAL DINNER TO BRING THE ENERGY WITH BESTSELLING AUTHOR
GREATER DES MOINES, Iowa, Oct. 27, 2025 /PRNewswire/ -- The Greater Des…
ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium
Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM),…
Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”)…
Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION Platform at the European Society of Medical Oncology Annual Congress
October 19, 2025 10:00 ET | Source: AVACTA GROUP PLC Median progression…
